Immunological profiling of TNBC indicates the tumor microenvironment (TME) has higher level of lymphocyte infiltration, tumor mutational burden rate7, 8 and programmed cell death receptor ligand 1 (PD‐L1) expression than other breast cancer subtypes.9 The gene discussed is CD274; the disease is neoplasm.